The RIO Trial’s Viral Rebound Data Just Complicated Every HIV Functional Cure Strategy on the Market
Phase 2 RIO trial shows 3BNC117-LS and 10-1074-LS delay HIV viral rebound after treatment interruption, but resistance patterns raise...
Phase 2 RIO trial shows 3BNC117-LS and 10-1074-LS delay HIV viral rebound after treatment interruption, but resistance patterns raise...
ENERGIZE-T's Phase 3 data shows mitapivat cut transfusion burden in 258 thalassaemia patients. Here's what the trial design reveals...
A landmark Nature Medicine RCT found AI improved clinician decisions but not patient outcomes, exposing the fatal flaw in...
The NSABP B-59/GeparDouze trial enrolled 1,550 TNBC patients and missed its primary endpoint. Atezolizumab's Phase 3 failure reveals a...
Dubai Health's rapid whole-genome sequencing rollout for critically ill children delivers diagnostic yields that dwarf standard testing, but exposes...
A UK NHS psilocybin trial exposes the standardization gap threatening psychedelic drug approval — therapist training, setting protocols, and...
AbbVie's Viti-Up trials showed upadacitinib 15mg hit F-VASI 75 in vitiligo across two Phase 3 studies—here's what the trial...
71% of US hospitals now deploy predictive AI, but validation frameworks lag dangerously behind. Here's what that gap means...
FDA cleared RiboX's RXIM002 IND for the first circular RNA-based in vivo CAR-T therapy — here's what it means...
A Lancet Psychiatry IPD meta-analysis of six antipsychotic trials shows hostility resolves weeks before negative symptoms—exposing a critical flaw...